Heterobivalent Imaging Agents for Simultaneous Targeting Prostate-Specific Membrane Antigen (PSMA) and Hepsin

2011 ◽  
Author(s):  
Youngjoo Byun
2008 ◽  
Vol 51 (24) ◽  
pp. 7933-7943 ◽  
Author(s):  
Ying Chen ◽  
Catherine A. Foss ◽  
Youngjoo Byun ◽  
Sridhar Nimmagadda ◽  
Mrudula Pullambhatla ◽  
...  

2012 ◽  
Vol 23 (12) ◽  
pp. 2377-2385 ◽  
Author(s):  
Ying Chen ◽  
Mrudula Pullambhatla ◽  
Sangeeta R. Banerjee. ◽  
Youngjoo Byun ◽  
Marigo Stathis ◽  
...  

2013 ◽  
Vol 56 (15) ◽  
pp. 6108-6121 ◽  
Author(s):  
Sangeeta Ray Banerjee ◽  
Mrudula Pullambhatla ◽  
Catherine A. Foss ◽  
Alexander Falk ◽  
Youngjoo Byun ◽  
...  

2013 ◽  
Vol 21 (5) ◽  
pp. 565-573 ◽  
Author(s):  
Youngjoo Byun ◽  
Mrudula Pullambhatla ◽  
Haofan Wang ◽  
Ronnie C. Mease ◽  
Martin G. Pomper

Diagnostics ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 1108
Author(s):  
Panagiotis J. Vlachostergios ◽  
Ioannis Zachos ◽  
Vassilios Tzortzis

Theranostics of prostate cancer (PC) represents a growing area of development of imaging agents and targeted radionuclide therapeutics against a major target, prostate specific membrane antigen (PSMA). In view of the encouraging efficacy from the use of 177Lu and other radionuclides in metastatic castration-resistant prostate cancer (mCRPC), it is becoming increasingly important to identify surrogate markers that can help predict which patients are more likely to respond and experience improved survival. This review discusses potential predictors of efficacy of PSMA-targeted radionuclide therapies (TRT) segregated in three major categories: imaging, clinical and molecular.


Sign in / Sign up

Export Citation Format

Share Document